Identification of early molecular markers for breast cancer by Kretschmer, Céline et al.
RESEARCH Open Access
Identification of early molecular markers for
breast cancer
Céline Kretschmer
1*, Anja Sterner-Kock
2, Friederike Siedentopf
3, Winfried Schoenegg
3, Peter M Schlag
4,
Wolfgang Kemmner
1
Abstract
Background: The ductal carcinoma in situ (DCIS) of the mammary gland represents an early, pre-invasive stage in
the development of invasive breast carcinoma. Since DCIS is a curable disease, it would be highly desirable to
identify molecular markers that allow early detection. Mice transgenic for the WAP-SV40 early genome region were
used as a model for DCIS development. Gene expression profiling was carried out on DCIS-bearing mice and
control animals. Additionally, a set of human DCIS and invasive mammary tumors were analyzed in a similar
fashion. Enhanced expression of these marker genes in human and murine samples was validated by quantitative
RT-PCR. Besides, marker gene expression was also validated by immunohistochemistry of human samples.
Furthermore in silico analyses using an online microarray database were performed.
Results: In DCIS-mice seven genes were identified that were significantly up-regulated in DCIS: DEPDC1, NUSAP1,
EXO1, RRM2, FOXM1, MUC1 and SPP1. A similar up-regulation of homologues of the murine genes was observed
in human DCIS samples. Enhanced expression of these genes in DCIS and IDC (invasive ductal carcinoma) was
validated by quantitative RT-PCR and immunohistochemistry.
Conclusions: By comparing murine markers for the ductal carcinoma in situ (DCIS) of the mammary gland with
genes up-regulated in human DCIS-samples we were able to identify a set of genes which might allow early
detection of DCIS and invasive carcinomas in the future. The similarities between gene expression in DCIS and
invasive carcinomas in our data suggest that the early detection and treatment of DCIS is of utmost relevance for
the survival of patients who are at high risk of developing breast carcinomas.
Background
Early diagnosis and administration of effective treatment
is the best strategy to combat cancer [1]. Starting in the
early 1980 s, the increasing use of mammography
screens has resulted in an increase in diagnosis of the
ductal carcinoma in situ (DCIS), especially among
w o m e nm o r et h a n5 0y e a r so fa g e[ 2 ] .D C I Sr e p r e s e n t s
20-45% of all new cases of mammographically detected
breast cancer, and about 10% of all breast carcinomas
[3]. Up to 50% of DCIS lesions progress to invasive
breast cancer, but there is tremendous variability in the
time of progression to invasive disease [4]. Today most
DCIS cases are identified as suspicious microcalcifica-
tions through mammography. However, the accuracy of
mammography in diagnosing DCIS is suboptimal [4].
The main drawback with respect to DCIS is that mam-
mography often underestimates both the pathologic
extent of DCIS and the number of tumour foci in
patients with multifocal disease [2]. Early detection of
DCIS is very important because it is a highly curable
disease, with a 10-year cancer-specific survival rate of
over 97% [3].
Therefore, biomarkers for DCIS are needed. In many
types of carcinomas, biomarkers have enhanced our abil-
ity for diagnosis, prognosis, and for therapy prediction. In
general, an appropriate biomarker should be useful in
defining risks and identifying the early stages of carcino-
genesis. Furthermore, biomarkers can be analyzed in a
noninvasive and economic way and therefore it is worth
investing in the search for more biomarkers [5].
The use of microarray technologies for gene expres-
sion profiling provides insight into the molecular basis
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DCIS have been published to date and most focus on
the identification of progression-associated genes by
comparison of in situ and invasive disease [6-8]. Gene
expression profiling of DCIS is hindered by the limited
numbers of samples available. To overcome the latter
problem, our study used a transgenic mouse model for
DCIS [9]. Mice were transgenic for the WAP-SV40 early
genome region, so that expression of the SV40 oncogene
is activated by lactation. The use of these transgenic ani-
mals offers the possibility of determining tumour-initiat-
ing factors and investigating gene expression at different
stages of tumour development.
In the present work, we identified molecular markers
for the ductal carcinoma in situ. Marker genes identified
in the WAP-TNP8 mouse model were further investi-
gated in a small human DCIS cohort. Identification of
markers for DCIS and early invasive tumours is impor-
tant for early detection and the development of
improved therapeutic strategies.
Materials and methods
Mice
WAP-TNP8 animals, which selectively synthesize the T/
t-antigen under the control of the WAP promoter in
mammary gland epithelial cells, were used for this study
[9]. In these mice the SV40 large tumour antigen is spe-
cifically induced by lactation. As a consequence of con-
tinuous expression of the oncogene, the animals develop
multifocal DCIS and consequently invasive carcinoma.
In general, the SV40-Tag system has very well docu-
mented intraluminal lesions which have been thoroughly
analyzed with histology, immunohistochemistry, whole
mounts and electron microscopy. These early lesions are
typically solid masses of poorly differentiated cells with
relatively compact hyperchromatic nuclei and scanty
cytoplasm. They resemble some forms of human intra-
ductal carcinomas [10]. WAP-TNP8 mice show rapidly
growing, palpable tumours which are evident on average
4 months after induction. DCIS lesions of the transgenic
mice exhibit distinct architectural and cytological
features which closely resemble those commonly present
in humans. The tumours mostly display a poorly differ-
entiated solid or even anaplastic morphology, well differ-
entiated tumours are rarely found. More precisely,
WAP-T-NP8 mice show cribriform morphology of in
situ carcinoma [9].
Wildtype mice and transgenic mice before lactation
were used as negative controls, so that changes simply
related to the transgenic profile could be ruled out.
Mice were analysed one month after lactation (abbre-
viated as 1 m), two months after lactation (2 m), three
months after lactation (3 m), four months after lactation
(4 m) and five months after lactation (5 m). In this way
we were able to study the development of DCIS at dif-
ferent time points. Similarly, invasive ductal carcinomas
(IDC) were investigated and served as a positive control.
Invasive tumors were obtained from mice taken at 4 or
5 months after lactation. Each group consisted of at
least seven mice. For subsequent analysis, mice were
sacrificed and mammary glands were dissected. From
each mouse four milk ducts were prepared. One part of
each mammary gland was cryopreserved in liquid nitro-
gen and stored at -80°C for RNA preparation and
another part was fixed overnight in 5% formaldehyde
and embedded in paraffin.
Human tissue
Nineteen freshly frozen human breast tumour samples
were obtained from the Robert-Rössle-Biobank at the
ECRC (Experimental and Clinical Research Center). Tis-
sue samples were cryopreserved immediately after sur-
gery in liquid nitrogen and stored at -80°C. All
participants have given written, informed consent. The
study was approved by the local ethics committee
(Charité Universitätsmedizin Berlin). The patient cohort
consisted of nine DCIS, five invasive ductal carcinoma
(IDC) and five healthy control samples obtained from
patients with breast reduction surgery. A second panel
consisting of human formalin-fixed paraffin-embedded
(FFPE) tissue samples was used for immunohistochem-
ical stainings. The panel consisted of 5 healthy, 10 DCIS
and 5 IDC. DCIS samples were distinguished according
to their grade (5 low grade DCIS/5 high grade DCIS).
All samples were reviewed for histological classification
according to nuclear grade and classified as low, inter-
mediate, and high nuclear grade; additionally, the TNM-
Stage and hormone receptor status were determined.
RNA isolation, amplification and microarray analysis
RNA extraction from murine samples was performed
using Qiagen RNeasy mini kit (Qiagen, Hilden,
Germany) with on column DNAse I digestion in accor-
dance with the manufacturer’s guide. Human RNA was
isolated with RNeasy Lipid Tissue Mini Kit (Qiagen).
RNA quality was checked on Agilent 2100 Bioanalyzer
(Agilent Technologies, Böblingen, Germany). For further
analysis only samples with a RIN (RNA integrity num-
ber) of more than seven were taken.
Two-round linear amplification, using 50 ng total
RNA, was carried out for the murine samples according
to the GeneChip
® Two-Cycle Target Labelling protocol
(Affymetrix, Santa Clara, CA, USA). In human samples
c R N Aw a sa m p l i f i e df r o m1μgo ft o t a lR N Au s i n gt h e
GeneChip
® One-Cycle Target Labelling Kit (Affymetrix).
Quantities of in vitro transcription and fragmentation
products were assessed using the Agilent 2100 Bioanaly-
zer. Labelled and fragmented cRNA was hybridized for
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Genome 430 2.0 or Human Genome U133 plus 2.0
Arrays. Hybridized arrays were scanned using the Gene-
Chip Scanner 3000.
Statistical analysis
An initial analysis was performed using the Affymetrix
Microarray Suite 5.0 (MAS5) software. The percentage
of present calls, background noise, the scaling factor,
and the ratio of 3’ to 5’ hybridization for GAPDH and
b-actin were used to assess quality of hybridization. Raw
i m a g ed a t aw e r ec o n v e r t e dt oC E Lf i l e su s i n gt h eA f f y -
metrix GeneChip Operating Software (GCOS). For adja-
cent analyses of microarray data, the GeneSpring GX
10.0 Software (Agilent Technologies) was used. GCRMA
(GC robust multiarray average) was used to perform
background correction and normalization. The mouse
data is deposited as GEO series GSE21444, http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=btetzoskmeo-
guzg&acc=GSE21444, and the human as GSE21422,
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=lhsfdsoicaekcho&acc=GSE21422.
In order to identify differentially expressed genes
between controls and samples taken at early time points
(month 2-3 after lactation), as well as between controls
and tumours, probe sets were filtered using the Welch-
Test (unpaired T-test; unequal variance) with Benjamini
and Hochberg False Discovery Rate. The fold-change
threshold was 5.0 and the corrected p-value was set to ≤
0.01. Volcano Plots visualize all probe sets according to
corrected p-value and fold change. Using a Venn dia-
gram, probe sets present in both lists were selected. The
annotations of each probe set were obtained from the
Affymetrix’s NetAffx™ database. Two-dimensional
unsupervised and supervised hierarchical clustering
using Euclidean distance as distance function and com-
plete linkage were performed. This method groups sam-
ples on the basis of similarity in their expression
pattern.
Quantitative RT-PCR
Quantitative RT-PCR was performed using TaqMan
®
Gene Expression Assays and the ABI Prism™ 7900 HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Gene Expression Assay IDs are listed in
additional file 1 (Table S1 +S2). For the murine samples,
the RNA UltraSense™ One-Step Quantitative RT-PCR
System (Invitrogen, Carlsbad, CA, USA) was used. The
procedure was performed in accordance with the manu-
facturer’s guide. For human RNA, cDNA synthesis was
done using Oligo(dT) primers and SuperScript II. For
the relative quantification of gene expression, triplicate
reactions were conducted. The expression of b-actin
served as an internal control because b-actin expression
levels were consistent throughout all samples through
the cDNA microarray data. Relative expression was cal-
culated according to the ΔΔCt method [11] using an
internal reference sample as calibrator.
Immunohistochemistry and H&E staining
Thin paraffin sections of the murine mammary glands
(2-4 μm) were stained with haematoxylin and eosin
according to standard procedures and histomorphologi-
cally evaluated by light microscopy. After deparaffinisa-
tion and rehydration, human tissue samples were boiled
in citrate buffer (pH 6.0) for 5 min. Endogenous peroxi-
dase was blocked using the DAKO Biotin Blocking Sys-
tem (DAKO, Glostrup, Denmark). Primary antibodies
(additional file 1, Table S3) were mostly applied (1:100)
for 1-2 h at room temperature. For each antibody, inter-
nal and external controls were included in the experi-
ments. In negative controls the primary antibody was
omitted. Sites of antigen-antibody binding were detected
using biotinylated anti-mouse/rabbit/goat antibodies
(Vector Laboratories, Burlingame, CA, USA). The chro-
mogen used was Neufuchsin (Merck, Darmstadt,
Germany). Slides were counterstained with haematoxylin
and after dehydration were mounted in Entellan.
For each protein multiple immunohistochemical
stainings were performed (5 healthy,5 low grade DCIS,
5 high grade DCIS and 5 IDC). A semi-quantitative
scoring system was used for the evaluation of the
immunohistochemical staining (Table 1). Figures show
representative pictures.
Results
Identification of murine DCIS markers
Gene expression patterns of control samples, of samples
taken at different time points after lactation, and of
invasive breast tumours (IDC) from 40 mice (five sam-
ples per group) were analysed. Animals examined one
month after activation of the oncogene were excluded
from further analysis because of artifacts due to
Table 1 Staining pattern of the immunohistochemical
analysis of different human mammary tissue samples
using a semi-quantitative scoring system
healthy control low grade DCIS high grade DCIS IDC
MUC1 - +++ +++ +++
SPP1 -/+ +++ +++ +++
RRM2 - +++ +++ +++
FOXM1 + +++ +++ +++
DEPDC1 + +++ +++ ++++
NUSAP1 - +++ +++ +++
- = no imunoreactive cells, + = 1-5 immunoreactive cells, ++ = 5-10
immunoreactive cells, +++ = 10-100 immunoreactive cells, ++++ = >100
immunoreactive cells. Average number of cells per high power field is given,
5 high power fields were evaluated.
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performed. The majority of DCIS arises by month three
or later.
First a t-test was conducted comparing the control
groups (wild type mice + mice before lactation) with mice
taken two and three months after lactation. This compari-
son revealed 230 probe sets which are differentially
expressed between control samples and mice in which the
development of DCIS had already been induced. A second
t-test was conducted in order to compare controls and
invasive mammary tumours. This procedure resulted in a
list of 2398 probe sets which were differentially expressed
between controls and invasive mammary tumours. To
obtain tumour-specific genes that are already up-regulated
in DCIS, only genes present in both lists were used for
further analysis. A total of 173 probe sets met these cri-
teria and were considered as potential candidate genes for
early DCIS detection. These 173 probe sets cover 140
genes (additional file 1, Table S4).
Supervised hierarchical clustering using the 140 candi-
date genes revealed tight clustering of murine samples
of the same month after lactation (Figure 1A). The vast
majority of the 140 candidate genes were up-regulated
in DCIS and tumour samples. As the pattern and length
of the branches reflects the relatedness of the samples,
these 140 genes clearly distinguish between control sam-
ples and malignant samples. Besides, it is obvious that
the samples of the late time points after lactation (3 - 5
months) exhibited an expression of the 140 genes simi-
lar to that of invasive tumour samples.
In order to identify a minimal set of genes as final
candidates, the distribution of the expression values of
the 140 significantly changed candidate genes was inves-
tigated. Only genes showing a enhanced expression in
the malignant samples were considered. Genes which
showed constant up-regulation during DCIS-develop-
ment and low variance within the groups were chosen
as final marker genes. These are: MUC1, SPP1, RRM2,
FOXM1, EXO1, NUSAP1 and DEPDC1. Using these
seven genes for supervised hierarchical clustering
allowed us to separate healthy control samples from all
other samples. Again, the tumour samples clustered in
the same branch as most of the samples of the late time
points (3, 4 and 5 months) (Figure 1B).
To confirm the microarray results, the expression of
the seven marker genes was validated by quantitative
RT-PCR (Figure 2A). Each group consisted of seven
murine samples. Results confirmed very well the find-
ings of the microarray analysis. A comparison of micro-
array and qRT-PCR box plots showed nearly identical
pictures, hence only the RT-PCR results are shown here.
With the exception of two cases, the expression of the
marker genes was already significantly up-regulated two
months after lactation, although in histological
Figure 1 Microarray analysis of murine samples. A: Supervised hierarchical clustering using 173 probe sets (= 140 genes) overexpressed in
mice taken 2-3 months after lactation and in IDC of WAP-TNP8 mice. Each row represents a probe set and each column a sample. The length
and the subdivision of branches display the relation of the samples based on their expression. Each group contains samples obtained from five
mice. The time point of determination of gene expression was calculated as months after lactation (1 month, 2 months,...). As a positive control
IDCs (Tumor) were used. Additionally, wild type (WT = Balb/C) mice and mice without lactation (neg. contr) were used as negative controls. Red
indicates upregulation, green downregulation, and black no change. B: Supervised hierarchical clustering of the murine samples using the seven
marker genes clearly distinguishes between control samples and malignant samples.
Kretschmer et al. Molecular Cancer 2011, 10:15
http://www.molecular-cancer.com/content/10/1/15
Page 4 of 11investigations almost no DCIS was found. In the case of
FOXM1 and DEPDC1 up-regulation in month two was
not significant, but that had changed by month three. In
m o s to ft h eg e n e st h e r ew a sac o n t i n u o u si n c r e a s eo f
expression which reached the highest point in the IDC.
Analysis of human DCIS samples
As a next step we investigated the gene expression of
human DCIS samples. To this end we used a set of 19
samples consisting of five healthy controls, five invasive
tumours and nine DCIS samples. Expression profiles
Figure 2 Validation of the marker gene expression by RT-PCR. Relative expression is shown in Box - Whisker - Plots. Gray columns show a
50% range of the data surrounding the median; black lines within each column mark the median; circles mark outliers. Significance was calculated
with the Mann-Whitney-U test (P < = 0.05*, P < = 0.01**, P < = 0.001 three stars). A: Panel of the murine samples. Controls are transgenic mice
before lactation (H). Months are calculated from the start of lactation (2 m = 2 months; 3 m = 3 months; 4 m = 4 months; 5 m = 5 months; IDC =
invasive ductal carcinoma). Each group contains 7 samples. B: Panel of human samples. Controls are healthy tissues from reduction plastics (H).
Kretschmer et al. Molecular Cancer 2011, 10:15
http://www.molecular-cancer.com/content/10/1/15
Page 5 of 11were recorded by Affymetrix U133 plus 2.0 GeneChips.
An unsupervised hierarchical clustering of the human
samples shows the healthy samples separated from the
DCIS and IDC samples. The DCIS samples showed a
comparative expression profile similar to that of the inva-
sive breast carcinomas (Data not shown). The human data
were analyzed in the same fashion as the murine samples.
However, we focused on the markers found already in the
murine analysis. Statistical analysis revealed a strong up-
regulation of the seven previously identified marker genes
in human DCIS as well. This led us to conclude that the
marker genes can be used as early detection markers also
for human DCIS. Hierarchical clustering using these seven
genes showed that DCIS and invasive carcinomas were
clearly separated from healthy samples (Figure 3). Within
the malignant branch DCIS and invasive carcinomas could
not be distinguished.
We also analysed genes which were significantly up-
regulated only in DCIS but not in IDC. In the murine
samples no such genes could be identified. In the
human samples 5 genes were found which showed sig-
nificant up-regulation in DCIS but not in IDC in com-
parison to healthy samples. The most interesting gene
was WNT5A. Recent work in a wide range of human
tumours has pointed to a critical role for the Wnt sig-
naling molecule Wnt-5a in malignant progression, but
there is conflicting evidence whether Wnt-5a has a
tumour-promoting or -suppressing role [12]. Expression
of WNT5A was not further investigated in the present
contribution.
Microarray results for the seven candidate genes
described above were validated by quantitative PCR.
Expression differences were highly significant between
healthy controls and DCIS samples (Figure 2B). In table
2 the most important reported functions of each of the
seven marker genes are depicted.
In order to further investigate the expression of
these candidate genes at the cellular level in vivo,w e
performed immunohistochemical analyses in a panel of
healthy human mammary gland tissue samples, DCIS
a n di n v a s i v eb r e a s tt u m o u r s .T od os ow eu s e da n o t h e r
set of formalin-fixed paraffin-embedded human tissue
samples. For each protein multiple immunohistochem-
ical stainings were performed (five samples per group).
Representative examples are shown in figure 4. For
EXO1 no specific antibody was found. Immunoreaction
of the marker genes in healthy tissues was negative or
very weak. However, immunoreaction in DCIS and IDC
samples in the majority of cases was very intense. The
expression of the protein was indicated by pink staining
(exemplarily see arrowhead). Positive staining was pre-
dominantly visible within the lumina of the ducts, pre-
dominantly epithelial cells showed a positive signal (See
arrows for examples). A positive staining was already
visible in the low grade DCIS samples. The staining pat-
tern was cytoplasmatic for SPP1, RRM2, FOXM1,
DEPDC1 and NUSAP1. Membranous as well as cyto-
plasmatic staining was visible for MUC1.
Discussion
The identification of gene expression signatures or
molecular markers in DCIS is hindered by difficulties in
obtaining sufficient numbers of frozen DCIS-samples
from the hospital. Thus, we first approached the pro-
blem using a mouse model. We choose the WAP-TNP8
mouse model of Schulze-Garg et al. [9] because it is a
well described model for DCIS and exhibits long latency
in developing invasive tumours. This animal model has
been used for detection of different tumour growth
kinetics by flat-panel volume computed tomography
[13], for the analysis of cell type-specific expression of
Casein kinase 1 epsilon (CK1e) [14] and for a molecular
imaging study of extradomain-b fibronectin (EDB-FN)
targeting neoangiogenesis by near-infrared fluorescence
[15]. In our study, we used this model for determining
tumour-initiating factors and investigating gene expres-
sion profiles at different stages of tumour development.
Gene profiling was confirmed within two panels of
human DCIS samples. A panel of fresh frozen human
samples was used for another gene expression profiling
analysis in order to verify whether the expression of the
marker genes identified in the murine samples agrees
with that found in the human samples. A second panel
of human FFPE samples, including high but also low
grade DCIS, was used for a validation of the expression
of the candidate genes on the protein level.
In this study, we identified seven marker genes which
are overexpressed in DCIS and invasive carcinomas and
allowed us to distinguish between healthy and DCIS
samples. Our marker genes include MUC1, SPP1,
R R M 2 ,F O X M 1 ,E X O 1 ,N U S A P 1a n dD E P D C 1 .S o m e
of these markers are already known to be related to
Figure 3 Microarray analysis of human samples.S u p e r v i s e d
hierarchical clustering using of the human samples using the seven
marker gene set clearly distinguishes between control samples and
malignant samples. Each row represents a probe set and each
column a sample. Red indicates upregulation, green
downregulation, and black no change.
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for breast cancer. In the future, such molecular markers
may allow an early detection of DCIS.
Epithelial mucin 1 (MUC1) is an accepted serum
tumour marker and cellular tumour antigen [16].
According to immunohistological studies MUC1 protein
expression is particular high in tumours, where it under-
goes changes in glycosylation and distribution [17].
However a low level of expression of MUC1 is also
found in healthy, undifferentiated (non-lactating) breast
tissue [18]. The correlation between MUC1 expression
and the clinical outcome of the patients is still under
debate. While some in-vitro studies showed that MUC1
overexpression promotes cellular invasion [19,20] inves-
tigations of MUC1 expression of breast carcinomas have
shown a better outcome for patients overexpressing
MUC1 [21]. MUC1 was found to be commonly up-
regulated in both DCIS and IDC [7]. Our results also
confirmed earlier findings showing that MUC1 is also
up-regulated on the protein level in DCIS [22].
Similarly, overexpression of Osteopontin (SPP1) has
been found in a variety of cancers, including breast,
lung, colorectal, stomach, ovarian cancers and mela-
noma [5,23]. SPP1 is a phosphorylated glycoprotein
secreted by several cell types, including those involved
in bone turnover and cells of the immune system [5,24].
SPP1 has been associated with breast cancer progres-
sion, invasion and metastasis [24-29] and is present in
elevated levels in the blood and plasma of some patients
with metastatic cancers [5]. We have found SPP1 to be
significantly up-regulated in DCIS. Previously, Reinholz
et al. investigated the expression of SPP1 in normal,
non-invasive, invasive and metastatic human breast can-
cer specimens by RT-PCR [30]. They showed that the
mRNA level of SPP1 increased in non-invasive, invasive
and metastatic breast tumour tissue compared to nor-
mal breast tissue. We found an increase in staining
intensity for SPP1 in DCIS samples compared to healthy
controls, which confirms a study by Oyama et al., who
detected positive staining of SPP1 using immunohisto-
chemistry on paraffin-embedded tissues in most cases of
low-grade cribiform and high-grade comedo-type ductal
carcinoma in situ [31].
RRM2, a ribonucleotid reductase (RR), was shown to
be overexpressed in human breast carcinoma tissue
(DCIS) [32]. RR is responsible for the de novo conver-
sion of ribonucleoside diphosphates to deoxyribonucleo-
side diphosphates that are essential for DNA synthesis
and repair [33,34]. RR consists of two subunits, M1
(RRM1) and M2 (RRM2). It is known that alterations in
RR levels can have significant effects on the biological
properties of cells, including tumour promotion and
tumour progression. In our findings, RRM2 was signifi-
cantly up-regulated on the RNA as well as on the pro-
tein level.
Likewise, the transcription factor forkhead box M1
(FOXM1) was found to be differentially expressed in
most solid tumours [35]. FOXM1 stimulates prolifera-
tion and cell cycle progression by promoting entry into
both S-phase and mitosis. In addition, it plays a role in
the proper execution of mitosis. FOXM1 is implicated
in the tumourigenesis of more than 20 types of human
tumours and contributes to both tumour initiation and
progression [36]. FOXM1 is broadly expressed in breast
Table 2 Overview of the main features of the candidate genes. Human Entrez Gene ID is shown in the last column
Symbol Name Go terms: biological process; molecular function GO terms: cellular
component
Entrez
GeneID
MUC1 mucin 1, cell surface
associated
hormone activity extracellular region, nucleus,
cytoplasm, integral to
membrane
4582
SPP1 secreted
phosphoprotein 1
ossification, cell adhesion; cytokine activity, protein binding extracellular region 6696
RRM2 ribonucleotide
reductase M2
polypeptide
DNA replication, deoxyribonucleoside diphosphate metabolic process,
oxidation reduction; ribonucleoside-diphosphate reductase activity, iron
ion binding, protein binding, oxidoreductase activity
cytoplasm, cytosol 6241
FOXM1 forkhead box M1 regulation of transcription, DNA-dependent, vasculogenesis, positive
regulation of cell proliferation; DNA binding, transcription factor activity,
protein binding
nucleus 2305
EXO1 exonuclease 1 DNA repair, mismatch repair, DNA recombination, immune response,
meiosis; DNA binding, catalytic activity, exonuclease activity,
endonuclease activity, ribonuclease H activity, protein binding, hydrolase
activity
nucleus 9156
DEPDC1 DEP domain
containing 1
signal transduction, intracellular signaling cascade; GTPase activator
activity
intracellular, nucleus 55635
NUSAP1 nucleolar and
spindle associated
protein 1
mitotic sister chromatid segregation, cell cycle, mitosis, establishment of
mitotic spindle localization, cell division; DNA binding, microtubule
binding
nucleus, cytoplasm,
microtubule
51203
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increased in transformed breast epithelial cell lines.
Consistently, FOXM1 expression is specifically elevated
in breast carcinomas [37]. Using immunohistochemistry,
Bektas et al. analysed FOXM1 expression in human
invasive breast carcinomas and normal breast tissues on
a tissue microarray [38]. In contrast to what could be
expected from GO-analysis (Table 2) they found a
strong cytoplasmatic expression of the transcription fac-
tor FOXM1, resulting most likely from its strong over-
e x p r e s s i o n .A d d i t i o n a l l y ,u s i n gR T - P C R ,F O X M 1w a s
found to be overexpressed in breast cancer in compari-
son to normal breast tissue both on the RNA and pro-
tein level. Furthermore, FOXM1 was found to be
overexpressed during progression from DCIS to invasive
breast cancer [7]. Our findings confirm these results.
FOXM1 was significantly overexpressed already on the
DCIS level and was even higher expressed in IDC.
In contrast, overexpression of EXO1, NUSAP1 and
DEPDC1 in IDC and DCIS had not yet been described.
We found these genes significantly up-regulated in
DCIS as well as in IDC. EXO1 (exonuclease 1) has been
Figure 4 Histological analysis of markers genes. Protein expression was determined by immunohistochemistry using sections from Formalin-
fixed paraffin-embedded tissue (A: MUC1, B: SPP1, C: RRM2, D: FOXM1, E: DEPDC1, F: NUSAP1). For each protein, expression is shown in human
breast tissue with a rising degree of malignancy (healthy, DCIS, invasive breast tumour). Specific signals are represented by pink staining
(arrowhead) (counterstained with haematoxylin, original magnification 400×, bars:100 μm). The inserts depict the negative controls as a
reference.
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pathways that include DNA repair, recombination, repli-
cation, and telomere integrity. This makes EXO1 a logi-
cal target for mutation during oncogenesis [39].
However, Rassmussen et al. have shown high expression
levels of human EXO1 transcripts in liver cancer cell
lines and in colon and pancreas adenocarcinomas, but
not in the corresponding non-neoplastic tissue [40].
This is a first hint that EXO1 is up-regulated in tumours.
Nucleolar spindle-associated protein (NUSAP1) was
identified in 2003 as a novel 55-kD vertebrate protein
with selective expression in proliferating cells [41].
mRNA and protein levels of NUSP1 peak at the transi-
tion of G2 to mitosis and abruptly decline after cell
division. Interestingly, NUSAP1 was found to be up-
regulated in melanoma cells by gene expression profiling
of a series of melanoma cell lines [42]. Proteins such as
NUSAP that show little or no expression in G1 and G0
may be reliable histochemical markers for proliferation
and might therefore be useful for cancer prognosis [41].
NUSAP1 expression was significantly increased in DCIS
and IDC in our study and is therefore a promising new
tumour marker. DEPDC1 (DEP domain containing 1) is
also a newly detected gene. Kanehira et al. identified
DEPDC1 as a novel gene that is highly overexpressed in
bladder cancer samples, but not expressed in any
human organs (heart, liver, kidney, lung) except the tes-
tis [43]. Our findings show that DEPDC1 is significantly
up-regulated in DCIS and IDC. Preliminary results from
a study of the functional relevance of DEPDC1 show
that it seems to be an important gene for proliferation
as well as for migration and invasion (C.S. manuscript
in progress).
We found that the seven putative marker genes are
strongly up-regulated in mice and in human DCIS sam-
ples. This reveals that the mouse model we used reflects
human breast cancer development. Previously, Klein et
al. [44] compared the expression profile of 24 human
b r e a s tt u m o u r sa n ds i xW A P - S V T / tm i c eb r e a s t
tumours. They found 597 genes which are overex-
pressed in breast cancer in mice [44]. Their list also
contains DEPDC1, NUSAP1, MUC1, EXO1, and RRM2.
Some of our marker genes have been described pre-
viously in human breast cancer. In a 22-gene signature
investigated by Martin et al. [45], FOXM1 and RRM2
were included. This signature accurately predicts breast
cancer outcome [45]. Additionally, Ma et al. developed a
gene expression index for tumour grade in breast cancer
patients which included RRM2 [6]. This is further evi-
dence that the candidate genes we identified are impor-
tant in tumour development.
Candidate genes were further validated using Onco-
mine http://www.oncomine.org, a database for online
cancer gene expression analysis. In the data set of
Richardson et al. which compared normal breast tissue
with IDC, six of our seven marker genes are significantly
up-regulated in IDC [46]. Additionally, also using Onco-
mine to search for the tumour grade and the prognostic
impact, we found that all the marker genes except MUC1
were significant for prognosis in the calculation of this
database. Using a p-value of 0.001 these genes are up-
regulated in multiple expression analyses in patients with
a poor prognosis. This is an indication that our panel of
marker genes could also be useful as a prognostic tool.
Looking at the tumour grade, all the genes except MUC1
and SPP1 were significantly up-regulated in samples with
ah i g ht u m o u rg r a d ei nO n c o m i n e .T h u s ,t h em a r k e r
genes might indicate a high grade of malignancy. One
explanation for this could be that in the analysis of the
human samples, we used predominantly samples with a
high tumour grade. On the other hand, in the case of the
murine samples, the specimens we investigated were
from a very early time point, where no DCIS (or few)
were pathologically found.
In accordance with recent gene expression studies, our
data support the hypothesis that critical molecular
events which have a profound influence on develop-
ment, progression and outcome of human breast cancer
occur at an early stage. Despite significant morphologic
differences between the different stages, expression pro-
files of early lesions are highly similar to the more
advanced, invasive lesions [47]. This has been demon-
s t r a t e da l s oo nt h ep r o t e i nl e v e l[ 4 8 ] .S o r l i ee ta l .
claimed that extensive studies of DCIS and other pre-
invasive stages of tumours will enhance this hypothesis
and substantiate the value of gene expression-based
classification in the prognosis of breast cancer at an
early stage [49]. Furthermore Ma et al. [50] showed that
the tumour microenvironment of invasive breast
tumours also participates in tumourigenesis even before
tumour cells invade into stroma. This is a further hint
that changes during breast cancer development occur at
a very early time point and that also the tumour micro-
environment plays an important role in the transition
f r o mp r e i n v a s i v et oi n v a s i v eg r o w t h .W et o o kas t e pi n
this direction by showing on the RNA level as well as
on the protein level that the marker genes we found are
already significantly up-regulated on the level of DCIS
and likewise later on the IDC level.
Conclusions
Summing up, we found seven putative tumour markers
which are strongly expressed at a very early stage of pre-
malignancy and preneoplasia of breast carcinomas. In
the future, the identified marker genes might allow an
early diagnosis of DCIS and thereby improve prognosis
of breast cancer. One next step will be to couple specific
probes for these marker genes to near-infrared-dyes and
Kretschmer et al. Molecular Cancer 2011, 10:15
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in-vivo animal model.
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